These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 31147963)

  • 1. Molecular profiling of anastatic cancer cells: potential role of the nuclear export pathway.
    Seervi M; Sumi S; Chandrasekharan A; Sharma AK; SanthoshKumar TR
    Cell Oncol (Dordr); 2019 Oct; 42(5):645-661. PubMed ID: 31147963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds.
    Crochiere M; Kashyap T; Kalid O; Shechter S; Klebanov B; Senapedis W; Saint-Martin JR; Landesman Y
    BMC Cancer; 2015 Nov; 15():910. PubMed ID: 26573568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
    Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
    Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A.
    Miyake T; Pradeep S; Wu SY; Rupaimoole R; Zand B; Wen Y; Gharpure KM; Nagaraja AS; Hu W; Cho MS; Dalton HJ; Previs RA; Taylor ML; Hisamatsu T; Kang Y; Liu T; Shacham S; McCauley D; Hawke DH; Wiktorowicz JE; Coleman RL; Sood AK
    Clin Cancer Res; 2015 Jul; 21(14):3286-97. PubMed ID: 25878333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy.
    Tan DS; Bedard PL; Kuruvilla J; Siu LL; Razak AR
    Cancer Discov; 2014 May; 4(5):527-37. PubMed ID: 24743138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anastasis: cell recovery mechanisms and potential role in cancer.
    Mohammed RN; Khosravi M; Rahman HS; Adili A; Kamali N; Soloshenkov PP; Thangavelu L; Saeedi H; Shomali N; Tamjidifar R; Isazadeh A; Aslaminabad R; Akbari M
    Cell Commun Signal; 2022 Jun; 20(1):81. PubMed ID: 35659306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The hippo kinase STK38 ensures functionality of XPO1.
    Martin AP; Camonis JH
    Cell Cycle; 2020 Nov; 19(22):2982-2995. PubMed ID: 33017560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear entrapment of p33ING1b by inhibition of exportin-1: A trigger of apoptosis in head and neck squamous cell cancer.
    Özdaş S
    Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):66-72. PubMed ID: 29729696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer.
    Chen Y; Camacho SC; Silvers TR; Razak AR; Gabrail NY; Gerecitano JF; Kalir E; Pereira E; Evans BR; Ramus SJ; Huang F; Priedigkeit N; Rodriguez E; Donovan M; Khan F; Kalir T; Sebra R; Uzilov A; Chen R; Sinha R; Halpert R; Billaud JN; Shacham S; McCauley D; Landesman Y; Rashal T; Kauffman M; Mirza MR; Mau-Sørensen M; Dottino P; Martignetti JA
    Clin Cancer Res; 2017 Mar; 23(6):1552-1563. PubMed ID: 27649553
    [No Abstract]   [Full Text] [Related]  

  • 10. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.
    Kashyap T; Argueta C; Aboukameel A; Unger TJ; Klebanov B; Mohammad RM; Muqbil I; Azmi AS; Drolen C; Senapedis W; Lee M; Kauffman M; Shacham S; Landesman Y
    Oncotarget; 2016 Nov; 7(48):78883-78895. PubMed ID: 27713151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
    Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM
    Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185.
    Tabe Y; Kojima K; Yamamoto S; Sekihara K; Matsushita H; Davis RE; Wang Z; Ma W; Ishizawa J; Kazuno S; Kauffman M; Shacham S; Fujimura T; Ueno T; Miida T; Andreeff M
    PLoS One; 2015; 10(9):e0137210. PubMed ID: 26340096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
    Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
    Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.
    Gandhi UH; Senapedis W; Baloglu E; Unger TJ; Chari A; Vogl D; Cornell RF
    Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):335-345. PubMed ID: 29610030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. XPO1-dependent nuclear export as a target for cancer therapy.
    Azizian NG; Li Y
    J Hematol Oncol; 2020 Jun; 13(1):61. PubMed ID: 32487143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human Exportin-1 is a Target for Combined Therapy of HIV and AIDS Related Lymphoma.
    Boons E; Vanstreels E; Jacquemyn M; Nogueira TC; Neggers JE; Vercruysse T; van den Oord J; Tamir S; Shacham S; Landesman Y; Snoeck R; Pannecouque C; Andrei G; Daelemans D
    EBioMedicine; 2015 Sep; 2(9):1102-13. PubMed ID: 26501108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer.
    Sexton R; Mahdi Z; Chaudhury R; Beydoun R; Aboukameel A; Khan HY; Baloglu E; Senapedis W; Landesman Y; Tesfaye A; Kim S; Philip PA; Azmi AS
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31569391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the XPO1-dependent nuclear export of E2F7 reverses anthracycline resistance in head and neck squamous cell carcinomas.
    Saenz-Ponce N; Pillay R; de Long LM; Kashyap T; Argueta C; Landesman Y; Hazar-Rethinam M; Boros S; Panizza B; Jacquemyn M; Daelemans D; Gannon OM; Saunders NA
    Sci Transl Med; 2018 Jun; 10(447):. PubMed ID: 29950445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The nuclear export protein exportin-1 in solid malignant tumours: From biology to clinical trials.
    Lai C; Xu L; Dai S
    Clin Transl Med; 2024 May; 14(5):e1684. PubMed ID: 38783482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importins and exportins as therapeutic targets in cancer.
    Mahipal A; Malafa M
    Pharmacol Ther; 2016 Aug; 164():135-43. PubMed ID: 27113410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.